Voyager Therapeutics, Inc. (VYGR)
3.42
-0.03
(-0.87%)
USD |
NASDAQ |
Sep 01, 16:00
3.42
0.00 (0.00%)
After-Hours: 18:49
Voyager Therapeutics Net Income (Quarterly) : -24.47M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -24.47M |
| March 31, 2026 | -27.94M |
| December 31, 2025 | -27.43M |
| September 30, 2025 | -27.89M |
| June 30, 2025 | -33.38M |
| March 31, 2025 | -31.02M |
| December 31, 2024 | -34.49M |
| September 30, 2024 | -9.044M |
| June 30, 2024 | -10.14M |
| March 31, 2024 | -11.33M |
| December 31, 2023 | 56.40M |
| September 30, 2023 | -25.90M |
| June 30, 2023 | -22.21M |
| March 31, 2023 | 124.04M |
| December 31, 2022 | -23.63M |
| September 30, 2022 | 17.62M |
| June 30, 2022 | -19.09M |
| March 31, 2022 | -21.32M |
| December 31, 2021 | 5.709M |
| September 30, 2021 | -25.14M |
| June 30, 2021 | -30.12M |
| March 31, 2021 | -21.65M |
| December 31, 2020 | -15.93M |
| Date | Value |
|---|---|
| September 30, 2020 | 85.61M |
| June 30, 2020 | -8.681M |
| March 31, 2020 | -24.26M |
| December 31, 2019 | -12.58M |
| September 30, 2019 | -15.01M |
| June 30, 2019 | 11.15M |
| March 31, 2019 | -27.17M |
| December 31, 2018 | -22.53M |
| September 30, 2018 | -20.29M |
| June 30, 2018 | -25.54M |
| March 31, 2018 | -19.93M |
| December 31, 2017 | -11.77M |
| September 30, 2017 | -23.35M |
| June 30, 2017 | -18.88M |
| March 31, 2017 | -16.65M |
| December 31, 2016 | -14.67M |
| September 30, 2016 | -8.996M |
| June 30, 2016 | -9.335M |
| March 31, 2016 | -7.188M |
| December 31, 2015 | -7.283M |
| September 30, 2015 | -3.917M |
| June 30, 2015 | -3.895M |
| March 31, 2015 | -14.58M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
| Imunon, Inc. | -2.814M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 3.165M |
| Total Expenses (Quarterly) | 27.64M |
| EPS Diluted (Quarterly) | -0.4042 |
| Enterprise Value | 127.62M |
| Gross Profit Margin (Quarterly) | 71.31% |
| Profit Margin (Quarterly) | -773.2% |
| Earnings Yield | -53.02% |
| Normalized Earnings Yield | -53.02 |